Report cover image

Bleeding Disorder Testing Market Insights, Competitive Landscape, and Market Forecast - 2033

Publisher Fairfield Market Research
Published Feb 04, 2026
Length 200 Pages
SKU # FCSL20854801

Description

The global Bleeding Disorder Testing Market is witnessing a significant upward trajectory, driven by advancements in diagnostic technologies, growing awareness about bleeding disorders, and rising prevalence of conditions such as hemophilia and von Willebrand disease. Bleeding disorders, characterized by an impaired ability of blood to clot, can lead to severe health complications if left untreated. Accurate and timely testing is critical for effective management and treatment, fueling demand for innovative diagnostic solutions. The market is projected to grow from USD 115.7 million in 2026 to USD 190.1 million by 2033, reflecting a healthy CAGR of 6.7%.

Market Insights

Bleeding disorder testing encompasses a range of diagnostic methods, including coagulation factor assays, genetic testing, platelet function tests, and more. The adoption of automated and high-throughput testing platforms has improved diagnostic accuracy and reduced turnaround time, enhancing patient outcomes. Additionally, integration of point-of-care testing in clinical settings is expanding access to diagnostics, particularly in regions with limited laboratory infrastructure.

The increasing prevalence of hemophilia A, hemophilia B, and von Willebrand disease worldwide has created a sustained demand for specialized testing services. According to epidemiological data, hemophilia A affects approximately 1 in 5,000 male births, while hemophilia B occurs in 1 in 30,000 male births. Von Willebrand disease is more common, affecting up to 1% of the global population. The growing emphasis on early diagnosis and personalized treatment approaches is further propelling market growth.

Drivers

Several key factors are driving the expansion of the bleeding disorder testing market:

1. Rising Prevalence of Bleeding Disorders: An increasing number of diagnosed cases globally is creating a consistent demand for accurate testing solutions.

2. Technological Advancements: Innovations such as next-generation sequencing (NGS), automated coagulation analyzers, and point-of-care testing devices are enhancing diagnostic precision.

3. Awareness and Screening Programs: Initiatives by healthcare authorities and patient advocacy groups are promoting early detection and management of bleeding disorders.

4. Increasing Healthcare Expenditure: Rising investments in healthcare infrastructure, particularly in developed and emerging economies, are boosting market accessibility and adoption.

5. Personalized Medicine Trends: Customized treatment plans based on accurate diagnostic data are driving the use of advanced testing platforms.

Business Opportunities

The bleeding disorder testing market presents multiple lucrative opportunities for key stakeholders:
• Expansion in Emerging Markets: Rapid urbanization, improved healthcare infrastructure, and rising awareness in Asia Pacific, Latin America, and the Middle East & Africa offer significant growth potential.
• Strategic Collaborations: Partnerships between diagnostic companies and healthcare providers can help expand testing accessibility and improve patient outcomes.
• Integration with Digital Health: Combining testing platforms with telemedicine and electronic health records can streamline diagnosis and monitoring, enhancing operational efficiency.
• R&D in Innovative Testing Solutions: Investment in novel diagnostic technologies, such as genetic panels and multi-factor assays, can capture unmet medical needs and create a competitive edge.

Regional Analysis

The bleeding disorder testing market demonstrates varied growth trends across different geographies:
• North America: The region holds a dominant share due to well-established healthcare infrastructure, high awareness of bleeding disorders, and widespread adoption of advanced diagnostic technologies. The U.S. is a major contributor, supported by strong government initiatives and reimbursement policies.
• Europe: High prevalence of bleeding disorders, coupled with increasing adoption of automated testing platforms and supportive regulatory frameworks, drives market growth in countries such as Germany, France, and the UK.
• Asia Pacific: Rapid healthcare development, increasing awareness, and a growing patient pool present strong opportunities for market expansion in China, India, and Japan.
• Latin America: Improving healthcare access and investment in laboratory infrastructure are fueling market penetration in countries like Brazil and Mexico.
• Middle East & Africa: Rising prevalence of inherited bleeding disorders and growing healthcare investments offer moderate growth potential, with focus on urban centers and private healthcare facilities.

Key Players

The market is highly competitive, with several established players focusing on innovation, product launches, and strategic partnerships to strengthen their market position. Prominent companies include:
• Siemens Healthineers
• Abbott Laboratories
• Roche Diagnostics
• bioMérieux SA
• Sysmex Corporation
• Danaher Corporation (Beckman Coulter & Leica Biosystems)
• Thermo Fisher Scientific Inc.
• Grifols, S.A.
• Instrumentation Laboratory (Werfen)
• Stago (Diagnostica Stago)
• HORIBA Medical
• Agilent Technologies, Inc.
• BD (Becton, Dickinson and Company)
• Instrumentation Laboratory Co.
• Charles River Laboratories International, Inc.

Market Segmentation

By Type
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

By Drug Class
• Plasma-derived Coagulation Factor Concentrates

 o Factor VIII

 o Factor IX

 o Factor for Willebrand Disease

 o Activated Prothrombin Complex Concentrate
• Recombinant Coagulation Factor Concentrates

 o Factor VIII

 o Factor for Von Willebrand Disease

 o Factor IX
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Please note: Delivery Timelines - 5 working days.

Table of Contents

200 Pages
1. Executive Summary
1.1. Global Bleeding Disorder Testing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Bleeding Disorder Testing Market Outlook, 2020 - 2033
3.1. Global Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
3.1.1. Hemophilia A
3.1.2. Hemophilia B
3.1.3. Von Willebrand Disease
3.1.4. Others
3.2. Global Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
3.2.1. Plasma-dervied Coagulation Factor Concentrates
3.2.1.1. Factor VIII
3.2.1.2. Factor IX
3.2.1.3. Factor for Willebrand Disease
3.2.1.4. Activated Prothrombin Complex Concentrate
3.2.2. Recombinant Coagulation Factor Concentrates
3.2.2.1. Factor VIII
3.2.2.2. Factor for Von Willebrand Disease
3.2.2.3. Factor IX
3.2.3. Desmopressin
3.2.4. Antifiberinolytics
3.2.5. Fibrin Sealants
3.2.6. Others
3.3. Global Bleeding Disorder Testing Market Outlook, by Region, Value (US$ Mn), 2020-2033
3.3.1. North America
3.3.2. Europe
3.3.3. Asia Pacific
3.3.4. Latin America
3.3.5. Middle East & Africa
4. North America Bleeding Disorder Testing Market Outlook, 2020 - 2033
4.1. North America Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
4.1.1. Hemophilia A
4.1.2. Hemophilia B
4.1.3. Von Willebrand Disease
4.1.4. Others
4.2. North America Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
4.2.1. Plasma-dervied Coagulation Factor Concentrates
4.2.1.1. Factor VIII
4.2.1.2. Factor IX
4.2.1.3. Factor for Willebrand Disease
4.2.1.4. Activated Prothrombin Complex Concentrate
4.2.2. Recombinant Coagulation Factor Concentrates
4.2.2.1. Factor VIII
4.2.2.2. Factor for Von Willebrand Disease
4.2.2.3. Factor IX
4.2.3. Desmopressin
4.2.4. Antifiberinolytics
4.2.5. Fibrin Sealants
4.2.6. Others
4.3. North America Bleeding Disorder Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
4.3.1. U.S. Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
4.3.2. U.S. Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
4.3.3. Canada Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
4.3.4. Canada Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
4.4. BPS Analysis/Market Attractiveness Analysis
5. Europe Bleeding Disorder Testing Market Outlook, 2020 - 2033
5.1. Europe Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
5.1.1. Hemophilia A
5.1.2. Hemophilia B
5.1.3. Von Willebrand Disease
5.1.4. Others
5.2. Europe Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
5.2.1. Plasma-dervied Coagulation Factor Concentrates
5.2.1.1. Factor VIII
5.2.1.2. Factor IX
5.2.1.3. Factor for Willebrand Disease
5.2.1.4. Activated Prothrombin Complex Concentrate
5.2.2. Recombinant Coagulation Factor Concentrates
5.2.2.1. Factor VIII
5.2.2.2. Factor for Von Willebrand Disease
5.2.2.3. Factor IX
5.2.3. Desmopressin
5.2.4. Antifiberinolytics
5.2.5. Fibrin Sealants
5.2.6. Others
5.3. Europe Bleeding Disorder Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
5.3.1. Germany Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.2. Germany Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.3. Italy Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.4. Italy Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.5. France Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.6. France Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.7. U.K. Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.8. U.K. Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.9. Spain Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.10. Spain Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.11. Russia Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.12. Russia Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.3.13. Rest of Europe Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
5.3.14. Rest of Europe Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
5.4. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Bleeding Disorder Testing Market Outlook, 2020 - 2033
6.1. Asia Pacific Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
6.1.1. Hemophilia A
6.1.2. Hemophilia B
6.1.3. Von Willebrand Disease
6.1.4. Others
6.2. Asia Pacific Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
6.2.1. Plasma-dervied Coagulation Factor Concentrates
6.2.1.1. Factor VIII
6.2.1.2. Factor IX
6.2.1.3. Factor for Willebrand Disease
6.2.1.4. Activated Prothrombin Complex Concentrate
6.2.2. Recombinant Coagulation Factor Concentrates
6.2.2.1. Factor VIII
6.2.2.2. Factor for Von Willebrand Disease
6.2.2.3. Factor IX
6.2.3. Desmopressin
6.2.4. Antifiberinolytics
6.2.5. Fibrin Sealants
6.2.6. Others
6.3. Asia Pacific Bleeding Disorder Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
6.3.1. China Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.2. China Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.3.3. Japan Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.4. Japan Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.3.5. South Korea Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.6. South Korea Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.3.7. India Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.8. India Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.3.9. Southeast Asia Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.10. Southeast Asia Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.3.11. Rest of SAO Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
6.3.12. Rest of SAO Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
6.4. BPS Analysis/Market Attractiveness Analysis
7. Latin America Bleeding Disorder Testing Market Outlook, 2020 - 2033
7.1. Latin America Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
7.1.1. Hemophilia A
7.1.2. Hemophilia B
7.1.3. Von Willebrand Disease
7.1.4. Others
7.2. Latin America Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
7.2.1. Plasma-dervied Coagulation Factor Concentrates
7.2.1.1. Factor VIII
7.2.1.2. Factor IX
7.2.1.3. Factor for Willebrand Disease
7.2.1.4. Activated Prothrombin Complex Concentrate
7.2.2. Recombinant Coagulation Factor Concentrates
7.2.2.1. Factor VIII
7.2.2.2. Factor for Von Willebrand Disease
7.2.2.3. Factor IX
7.2.3. Desmopressin
7.2.4. Antifiberinolytics
7.2.5. Fibrin Sealants
7.2.6. Others
7.3. Latin America Bleeding Disorder Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
7.3.1. Brazil Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
7.3.2. Brazil Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
7.3.3. Mexico Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
7.3.4. Mexico Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
7.3.5. Argentina Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
7.3.6. Argentina Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
7.3.7. Rest of LATAM Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
7.3.8. Rest of LATAM Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
7.4. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Bleeding Disorder Testing Market Outlook, 2020 - 2033
8.1. Middle East & Africa Bleeding Disorder Testing Market Outlook, by Type, Value (US$ Mn), 2020-2033
8.1.1. Hemophilia A
8.1.2. Hemophilia B
8.1.3. Von Willebrand Disease
8.1.4. Others
8.2. Middle East & Africa Bleeding Disorder Testing Market Outlook, by Drug Class, Value (US$ Mn), 2020-2033
8.2.1. Plasma-dervied Coagulation Factor Concentrates
8.2.1.1. Factor VIII
8.2.1.2. Factor IX
8.2.1.3. Factor for Willebrand Disease
8.2.1.4. Activated Prothrombin Complex Concentrate
8.2.2. Recombinant Coagulation Factor Concentrates
8.2.2.1. Factor VIII
8.2.2.2. Factor for Von Willebrand Disease
8.2.2.3. Factor IX
8.2.3. Desmopressin
8.2.4. Antifiberinolytics
8.2.5. Fibrin Sealants
8.2.6. Others
8.3. Middle East & Africa Bleeding Disorder Testing Market Outlook, by Country, Value (US$ Mn), 2020-2033
8.3.1. GCC Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
8.3.2. GCC Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
8.3.3. South Africa Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
8.3.4. South Africa Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
8.3.5. Egypt Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
8.3.6. Egypt Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
8.3.7. Nigeria Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
8.3.8. Nigeria Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
8.3.9. Rest of Middle East Bleeding Disorder Testing Market Outlook, by Type, 2020-2033
8.3.10. Rest of Middle East Bleeding Disorder Testing Market Outlook, by Drug Class, 2020-2033
8.4. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Siemens Healthineers
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Abbott Laboratories
9.4.3. Roche Diagnostics
9.4.4. bioMérieux SA
9.4.5. Sysmex Corporation
9.4.6. Danaher Corporation (Beckman Coulter & Leica Biosystems)
9.4.7. Thermo Fisher Scientific Inc.
9.4.8. Grifols, S.A.
9.4.9. Instrumentation Laboratory (Werfen)
9.4.10. Stago (Diagnostica Stago)
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us